We are advising the company on the funding round

Davis Polk is advising Bit Bio Limited in connection with its $50 million Series C funding round led by M&G Investments to scale human cell programming technology.

Davis Polk previously advised bit.bio in connection with its $30 million financing round led by M&G Investments in December 2024.

bit.bio is a synthetic biology company providing human cells for research, drug discovery and cell therapy. The company applies a patented safe harbour gene-targeting approach (opti-ox; Pawlowski 2017) to inducibly express transcription factor combinations that reprogram human induced pluripotent stem cells (iPSCs) into highly defined and mature human cell types. The company was spun out of the University of Cambridge in 2016 and has since raised funds from leading investors, including Arch Venture, Blueyard Capital, Charles River Laboratories, Foresite Capital, M&G, Milky Way, National Resilience, and Tencent.

M&G Investments is part of M&G plc, a savings and investments company with £365 billion of assets under management, as of 30 September, 2025. M&G plc has customers in the United Kingdom, Europe, the Americas and Asia, including individual savers and investors, life insurance policy holders and pension scheme members. M&G has invested through its Crossover strategy within its public equity business on behalf of M&G Life’s £130 billion With Profits Fund and its 4.5 million U.K. policyholders. Crossover provides patient growth equity to high-quality, fast-growing private companies, enabling their eventual crossover into public markets.

The Davis Polk corporate team includes partner Leo Borchardt, counsel William Tong and associate Gilbert Lim. Partner Matthew Yeowart and associate Dylan Jones are providing foreign direct investment advice. All members of the Davis Polk team are based in the London office.

Copy link to share post